Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,120Revenue $M64.5Net Margin (%)16.9Altman Z-Score2.9
Enterprise Value $M2,138EPS $0.6Operating Margin %28.3Piotroski F-Score7
P/E(ttm)206Beneish M-Score-3.5Pre-tax Margin (%)14.4Higher ROA y-yN
Price/Book58.510-y EBITDA Growth Rate %--Quick Ratio10.4Cash flow > EarningsY
Price/Sales36.35-y EBITDA Growth Rate %--Current Ratio10.6Lower Leverage y-yN
Price/Free Cash Flow283y-y EBITDA Growth Rate %9.0ROA % (ttm)5.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)22.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M19.7ROIC % (ttm)34.5Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDKen Fisher 2015-06-30 Reduce$75.67 - $100.9
($87.3)
$ 107.7823%Reduce 1.59%80,608
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 107.7875%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 107.78106%Reduce 99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 107.78106%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 107.78103%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 107.7866%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 107.7866%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 107.7862%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 107.78106%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 107.78138%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 107.78718%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 107.78922%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.14)
$ 107.78788%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.16)
$ 107.78567%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Berkman Charles SVP, Gen. Counsel & Secretary 2015-07-10Sell14,067$99.148.71view
FOEHR MATTHEW WPresident and COO 2015-06-26Sell12,500$100.976.74view
FOEHR MATTHEW WPresident and COO 2015-06-22Sell23,046$96.4511.75view
Herman Melanie JInterim CFO 2015-06-10Sell4,125$93.515.27view
HIGGINS JOHN LCEO 2015-06-09Sell10,000$92.8816.04view
Aryeh JasonDirector 2015-06-04Sell1,640$92.6816.29view
Aryeh JasonDirector 2015-05-20Sell9,240$87.3423.4view
DeSilva Nishan MVP, Finance & Strategy and CFO 2015-05-14Sell68,363$83.9128.45view
Patel SunilDirector 2015-03-19Sell4,591$74.4244.83view
Berkman Charles SVP, Gen. Counsel & Secretary 2015-03-16Sell11,264$74.5444.59view

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
dick Feb 13 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 

More From Other Websites
Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled... Jul 30 2015
Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled... Jul 30 2015
9:00 am Ligand Pharma enters into a commercial license and supply agreement with Sanofi (Jul 30 2015
Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma Jul 29 2015
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron... Jul 28 2015
Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog Jul 24 2015
AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog Jul 24 2015
Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a... Jul 24 2015
Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a... Jul 24 2015
Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog Jul 21 2015
Ligand to Report Second Quarter Results on August 4th Jul 16 2015
Ligand to Report Second Quarter Results on August 4th Jul 16 2015
Why Ligand Pharmaceuticals (LGND) Could Be an Impressive Growth Stock - Tale of the Tape Jul 15 2015
Trending Now: Ligand Pharmaceuticals Jul 06 2015
Life After Loeb: Ligand Pharmaceuticals Prospers In Stripped-Down Mode Jul 01 2015
Edited Transcript of LGND presentation 24-Jun-15 6:30pm GMT Jun 29 2015
Ligand to Participate in Four Upcoming Investor Conferences Jun 17 2015
Ligand to Participate in Four Upcoming Investor Conferences Jun 17 2015
Edited Transcript of LGND earnings conference call or presentation 11-May-15 1:00pm GMT Jun 17 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK